Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Hope S RugoEduardo J PennellaUnmesh GopalakrishnanMiguel Hernandez-BronchudJay HersonHans Friedrich KochSubramanian LoganathanSarika DeodharAshwani MarwahAlexey ManikhasIgor BondarenkoGuzel MukhametshinaGia NemsadzeJoseph D ParraMaria Luisa T Abesamis-TiambengKakhaber BaramidzeCharuwan AkewanlopIhor VynnychenkoVirote SriuranpongGopichand MamillapalliSirshendu RoyEduardo Patricio Yanez RuizAbhijit BarveAdolfo Fuentes-AlburoCornelius F WallerPublished in: Breast cancer research and treatment (2021)
This is the first phase 3 trial of a trastuzumab biosimilar to report long-term survival data similar to originator trastuzumab in patients with MBC. The comparable long-term OS between the trastuzumab-dkst and originator trastuzumab groups further supports the similarity of trastuzumab-dkst with originator trastuzumab and establishes trastuzumab-dkst as a safe and effective treatment option for patients with HER2-positive MBC. ClinicalTrials.gov NCT02472964; 6/16/2015.